Aetna Enhances Efforts to Streamline Experiences for Healthcare Professionals and Patients
Aetna Accelerates National Strategy to Simplify Healthcare for Providers and Patients Through Innovation, AI, and Integrated Care Models Aetna®, a CVS Health® company today announced significant progress on its ambitious,…
Breyanzi Approved as First CAR T Therapy for Relapsed/Refractory MZL
Bristol Myers Squibb’s Breyanzi Becomes First and Only CAR T Cell Therapy Approved by FDA for Relapsed or Refractory Marginal Zone Lymphoma Breyanzi® CD19-directed chimeric antigen receptor (CAR) T cell…
FDA Conditionally Approves EXZOLT™ CATTLE-CA1 for Screwworm Prevention and Treatment
Merck Animal Health Secures FDA Conditional Approval for EXZOLT™ CATTLE-CA1—A Groundbreaking Tool Against New World Screwworm and Cattle Fever Tick Merck Animal Health, known globally as MSD Animal Health outside…
Cipla Collaborates with Stempeutics to Launch Stem Cell Therapy for Knee Osteoarthritis
Cipla and Stempeutics Forge Landmark Partnership to Introduce India’s First Allogeneic Stem Cell Therapy for Knee Osteoarthritis Cipla Limited a global pharmaceutical leader with a legacy of patient-centric innovation—has officially…
Alnylam Pharmaceuticals Announces Board of Directors Updates
Alnylam Pharmaceuticals Announces Strategic Refresh of Board of Directors to Propel Next Phase of Growth Alnylam Pharmaceuticals, Inc.the global pioneer and leader in RNA interference (RNAi) therapeutics, today announced a…
BioNTech Meets Minimum Requirement for CureVac Exchange Offer
BioNTech Secures Overwhelming Shareholder Support, Meets Minimum Condition to Complete CureVac Exchange Offer BioNTech SE announced today that it has successfully met the minimum tender condition for its exchange offer…
Bristol Myers Squibb Advances ADEPT-2 Phase 3 Trial for Alzheimer’s-Related Psychosis
Bristol Myers Squibb Advances ADEPT-2 Phase 3 Trial for Alzheimer’s-Related Psychosis Following Rigorous Data Review and FDA Alignment Bristol Myers Squibb has announced a significant update regarding its ADEPT-2 Phase…
Pediatric Study Data on Bayer’s Investigational MRI Contrast Agent Showcased at RSNA 2025
Bayer Unveils Groundbreaking Pediatric Data for Investigational Low-Dose MRI Contrast Agent Gadoquatrane at RSNA 2025 Radiological Society of North America in Chicago, Bayer announced compelling new findings from the QUANTI…
Johnson & Johnson Partners with Naomi Watts to Spotlight Eye Exams as Essential Self-Care for Women Over 40
Johnson & Johnson and Naomi Watts Urge Women Over 40 to Embrace Eye Exams as a Foundational Act of Self-Care Johnson & Johnson Vision—a global leader in eye health—has joined…
Lilly and IU Partner to Broaden Hoosiers’ Access to Clinical Trials and Cutting-Edge Treatments
Lilly and Indiana University Forge Historic $40 Million Partnership to Revolutionize Clinical Trials and Expand Access to Cutting-Edge Therapies for Hoosiers Eli Lilly and Company and Indiana University (IU) have…
ICON Survey: Rising Trial Startup Delays Highlight Need for Human-Centred Site Activation
ICON Survey Exposes Escalating Delays in Clinical Trial Startups—Calls for Human-Centred Site Activation Solutions biotechnology, artificial intelligence, and precision medicine, the clinical trial landscape should be accelerating. Yet, a new…
Zoetis Showcases R&D Leadership and Long-Term Growth Potential in Innovation Webcast
Zoetis Unveils Strategic Vision for the Future of Animal Health at Innovation Webcast, Highlighting Robust R&D Pipeline and Multi-Billion-Dollar Growth Opportunities Zoetis Inc. the global leader in animal health, hosted…